Apellis Pharma Adds Venture Capital Investment
Tuesday, June 21, 2011 5:39:00 AM PDT | VentureDeal Staff
Louisville, Kentucky -- Apellis Pharmaceuticals has received $1.28 million in new venture capital financing, according to an SEC regulatory filing.
Apellis is in early-stage drug company focused on peptide drugs in the immunology space.
Investors in the financing were not disclosed. The company is still seeking an additional $1.25 million in financing, according to the filing.
Email Page | Print Page